

# Stephen R Bloom

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7919303/publications.pdf>

Version: 2024-02-01

28  
papers

932  
citations

623734

14  
h-index

526287

27  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1089  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e767-e782. | 3.6  | 16        |
| 2  | Hepatocyte cholesterol content modulates glucagon receptor signalling. <i>Molecular Metabolism</i> , 2022, 63, 101530.   | 6.5  | 4         |
| 3  | Genetic and biased agonist-mediated reductions in $\beta$ -arrestin recruitment prolong cAMP signaling at glucagon family receptors. <i>Journal of Biological Chemistry</i> , 2021, 296, 100133.         | 3.4  | 41        |
| 4  | Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking. <i>Molecular Pharmacology</i> , 2021, 100, 319-334.                             | 2.3  | 13        |
| 5  | Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1. <i>Biochemical Pharmacology</i> , 2021, 190, 114656.  | 4.4  | 8         |
| 6  | Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist. <i>Molecular Metabolism</i> , 2021, 51, 101242.  | 6.5  | 7         |
| 7  | Receptor Activity-Modifying Protein 2 (RAMP2) alters glucagon receptor trafficking in hepatocytes with functional effects on receptor signalling. <i>Molecular Metabolism</i> , 2021, 53, 101296.        | 6.5  | 23        |
| 8  | Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8404.             | 4.1  | 28        |
| 9  | Disconnect between signalling potency and <i>in vivo</i> efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. <i>Molecular Metabolism</i> , 2020, 37, 100991.     | 6.5  | 32        |
| 10 | The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 345-360.                 | 4.9  | 32        |
| 11 | Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide. <i>British Journal of Pharmacology</i> , 2020, 177, 3905-3923.           | 5.4  | 36        |
| 12 | Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 1151-1159.   | 5.0  | 9         |
| 13 | Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells. <i>PLoS Biology</i> , 2019, 17, e3000097.   | 5.6  | 61        |
| 14 | Targeting GLP-1 receptor trafficking to improve agonist efficacy. <i>Nature Communications</i> , 2018, 9, 1602.  | 12.8 | 162       |
| 15 | Control of insulin secretion by GLP-1. <i>Peptides</i> , 2018, 100, 75-84.   | 2.4  | 69        |
| 16 | A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic $\beta$ -Cells. <i>Diabetes</i> , 2018, 67, 385-399.                                 | 0.6  | 41        |
| 17 | Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases. <i>Endocrinology</i> , 2017, 158, 1755-1765.   | 2.8  | 16        |
| 18 | Potent Prearranged Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor. <i>ChemistryOpen</i> , 2017, 6, 501-505.  | 1.9  | 31        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | RAMP2 Influences Glucagon Receptor Pharmacology via Trafficking and Signaling. <i>Endocrinology</i> , 2017, 158, 2680-2693.   | 2.8  | 33        |
| 20 | Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. <i>Journal of Investigative Surgery</i> , 2017, 30, 162-169.   | 1.3  | 1         |
| 21 | Live demo: Platform for closed loop neuromodulation based on dual mode biosignals. , 2017, , .  |      | 2         |
| 22 | A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus. <i>BMJ Open</i> , 2017, 7, e018598. | 1.9  | 13        |
| 23 | Allosterische optische Steuerung eines Klasseâ€Bâ€Gâ€Proteinâ€gekoppelten Rezeptors. <i>Angewandte Chemie</i> , 2016, 128, 5961-5965.   | 2.0  | 10        |
| 24 | Allosteric Optical Control of a Class B Gâ€Proteinâ€Coupled Receptor. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 5865-5868.   | 13.8 | 45        |
| 25 | Pharmacokinetics and pharmacodynamics of subcutaneously administered PYY3â€36 and its analogues in vivo. <i>Lancet, The</i> , 2015, 385, S28.   | 13.7 | 4         |
| 26 | Learning curve of vessel cannulation in rats using cumulative sum analysis. <i>Journal of Surgical Research</i> , 2015, 193, 69-76.   | 1.6  | 3         |
| 27 | Effects of Elevating Colonic Propionate on Liver Fat Content in Adults with Nonâ€Alcoholic Fatty Liver Disease. <i>FASEB Journal</i> , 2015, 29, 385.2.   | 0.5  | 1         |
| 28 | Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia. <i>Diabetes</i> , 2013, 62, 1131-1138.                                      | 0.6  | 182       |